43 withdrawn. 43 Phase 3, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 43 | Withdrawn 43 |
| Phase 2 | 8 | Withdrawn 8 |
Follow Lung Diseases, Obstructive: new trials by email Literature Review of Lung Diseases, Obstructive trials Research Report on Lung Diseases, Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA) N0783, Alenia® (Formoterol 6 mcg / Budesonide 200 mcg) - Moderate Asthma | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2026-10-01 | 2026-10-23 | |
| Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray Dupilumab - Allergic Fungal Rhinosinusitis (AFRS), Chronic Rhinosinusitis (CRS) | Phase 3 | Withdrawn | National Institute on Deafness and Other Communication Disorders (NIDCD) | 2024-07-17 | 2024-07-25 | |
| Terbutaline Sulfate in Adults With Asthma Terbutaline - Asthma | Phase 2 / Phase 3 | Withdrawn | Kanecia Obie Zimmerman | 2023-07-07 | 2026-01-22 | |
| Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation Methacholine Chloride, Albuterol Sulfate HFA 0.09 mg (Reference), Albuterol Sulfate HFA 0.18 mg (Reference) - Bronchial Asthma | Phase 3 | Withdrawn | Aurobindo Pharma Ltd | 2022-04-01 | 2022-05-20 | |
| Investigating the Effects of QVM149 on MRI Ventilation Defects QVM149, High Dose Dual Therapy (ICS/LABA) - Asthma | Phase 3 | Withdrawn | Dr. Grace Parraga | 2021-12-01 | 2021-12-14 | |
| Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD Testosterone Enanthate, Placebo - COPD | Phase 2 / Phase 3 | Withdrawn | The University of Texas Medical Branch, Galveston | 2021-12-01 | 2022-02-02 | |
| Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI, Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI - Chronic Obstructive Pulmonary Disease | Phase 3 | Withdrawn | Neutec Ar-Ge San ve Tic A.Ş | 2021-09-03 | 2021-09-13 | |
| Efficacy of Magnesium Sulfate Bolus in Pediatric Patients With Bronchiolitis Magnesium Sulfate - Bronchiolitis, Viral | Phase 2 / Phase 3 | Withdrawn | University of Louisville | 2021-07-21 | 2026-05-11 | |
| Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection) Best Practice, Tocilizumab - Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease | Phase 3 | Withdrawn | Emory University | 2020-04-07 | 2020-06-18 | |
| Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma Beclomethasone 800 µg per day, Placebo, Beclomethasone 400 µg per day - Asthma | Phase 3 | Withdrawn | Adamis Pharmaceuticals Corporation | 2019-02-01 | 2019-07-17 | |
| Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma Placebo, 400 µg per day Beclomethasone, 200 µg per day Beclomethasone - Asthma | Phase 3 | Withdrawn | Adamis Pharmaceuticals Corporation | 2019-02-01 | 2019-07-17 | |
| Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma FF/UMEC/VI, FP/SAL, Tiotropium - Asthma | Phase 3 | Withdrawn | GlaxoSmithKline | 2019-01-18 | 2019-03-25 | |
| To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease BGF 320/14.4/9.6 µg MDI, BFF 320/9.6 µg - Chronic Obstructive Pulmonary Disease | Phase 3 | Withdrawn | Pearl Therapeutics, Inc. | 2018-04-16 | 2018-08-02 | |
| A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg, Fluticasone furoate 100 mcg + Vilanterol 25 mcg, Umeclidinium 62.5 mcg - Pulmonary Disease, Chronic Obstructive | Phase 3 | Withdrawn | GlaxoSmithKline | 2016-06-01 | 2016-07-22 | |
| A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home Setting Lebrikizumab, Prefilled Syringes - Asthma | Phase 3 | Withdrawn | Hoffmann-La Roche | 2015-09-29 | 2018-04-25 | |
| Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics Fluticasone propionate 100 mcg / salmeterol 50 mcg, Generic fluticasone propionate 100 mcg / salmeterol 50 mcg, Placebo - Asthma | Phase 3 | Withdrawn | Actavis Inc. | 2015-09-01 | 2019-07-05 | |
| Opioids for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease Morphine sulfate, Placebo - Chronic Obstructive Pulmonary Disease, Dyspnea | Phase 3 | Withdrawn | Flinders University | 2015-05-01 | 2016-01-12 | |
| Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma NVA237, Placebo to NVA237, salbutamol/ albuterol - Asthma | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2015-03-01 | 2015-04-13 | |
| Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients. NVA237, Tiotropium Respimat® - Pulmonary Disease, Chronic Obstructive | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2014-04-01 | 2016-08-22 | |
| A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD QVA149, fluticasone/salmeterol - Chronic Obstructive Pulmonary Disease | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2013-12-01 | 2013-11-11 |
Showing 20 of 43. Sign in to see all of them.
Asthma (21) · Pulmonary Disease, Chronic Obstructive (19) · Emphysema (4) · Bronchiolitis Obliterans Syndrome (3) · Asthma, Exercise-Induced (2) · Dyspnea (2) · Allergic Fungal Sinusitis (1) · Anemia (1) · Anxiety Disorders (1) · Bronchiolitis, Viral (1) · COVID-19 (1) · Chronic Pain (1) · Coronary Artery Disease (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1)
Respiratory Tract Diseases (43) · Lung Diseases (42) · Bronchial Diseases (25) · Immune System Diseases (24) · Pathological Conditions, Signs and Symptoms (22) · Hypersensitivity (21) · Hypersensitivity, Immediate (21) · Respiratory Hypersensitivity (21) · Chronic Disease (20) · Disease Attributes (20) · Pathologic Processes (20) · Bronchiolitis (4) · Bronchitis (4) · Bronchiolitis Obliterans (3)
Albuterol (5) · Fluticasone (4) · Fluticasone-Salmeterol Drug Combination (3) · Formoterol Fumarate (3) · Glycopyrrolate (3) · Salmeterol Xinafoate (3) · Beclomethasone (2) · Magnesium Sulfate (2) · Metered Dose Inhalers (2) · fluticasone furoate (2) · indacaterol-glycopyrronium combination (2) · montelukast (2) · Adrenal Cortex Hormones (1) · Adrenergic beta-Agonists (1) · Budesonide (1)
Novartis Pharmaceuticals (5) · GlaxoSmithKline (4) · Adamis Pharmaceuticals Corporation (2) · Aeris Therapeutics (2) · Hoffmann-La Roche (2) · Organon and Co (2) · University of Louisville (2) · Ache Laboratorios Farmaceuticos S.A. (1) · Actavis Inc. (1) · Alung Technologies (1) · Assistance Publique - Hôpitaux de Paris (1) · Aurobindo Pharma Ltd (1) · Bristol-Myers Squibb (1) · Children's Hospital Medical Center, Cincinnati (1) · Dr. Grace Parraga (1)
United States (10) · Germany (4) · Canada (3) · United Kingdom (3) · Argentina (1) · Austria (1) · Belgium (1) · Colombia (1) · Czechia (1) · France (1) · Hungary (1) · India (1) · Italy (1) · Netherlands (1) · Poland (1)
Dennis Carlo (2) · Ajay K Nooka (1) · Alyn H Morice, Professor (1) · Beverley Patterson, PhD (1) · Colin Reisner, MD (1) · David C Currow, MD, PhD (1) · Elliot Israel (1) · Felix Herth, Prof. Dr med (1) · Felix JF Herth, MD, PhD (1) · George Bakris, MD (1) · Grace E Parraga, PhD (1)
2017 (1), P30CA138292 (1), U10HL051823 (1), U10HL051831 (1), U10HL051834 (1), U10HL051843 (1), U10HL051845 (1), U10HL056443 (1), U10HL074073 (1), U10HL074204 (1), U10HL074206 (1), U10HL074208 (1), U10HL074212 (1), U10HL074218 (1), U10HL074225 (1)